Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging trial of KY1005 in moderate-to-severe atopic dermatitis
jRCT2011210072Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (4 arms), sponsored by Sanofi. Primary endpoint: Percentage change in EASI from baseline to Day 113. Started Jun 2022; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2011210072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210072.